FDA Approves Milsaperidone For Treatment of Schizophrenia and Bipolar I Disorder

The FDA approved milsaperidone (Bysanti) tablets for adult patients as a first-line therapy for the treatment of schizophrenia and for the acute management of manic or mixed episodes associated with bipolar I disorder.¹

"The Bysanti approval marks a significant step forward, offering patients and providers a reliable new treatment grounded in extensive clinical heritage," Mihael H. Polymeropoulos, MD, president, CEO, and chairman of the Board of Vanda Pharmaceuticals, said in a news release.¹ "Bysanti exemplifies a new era of accelerated innovation in drug development that can transform how we address unmet needs in behavioral health."

For pharmacists, the approval represents a unique regulatory milestone because although milsaperidone is classified as a new chemical entity, it has demonstrated bioequivalence to the established atypical antipsychotic iloperidone across the therapeutic dosing spectrum. This relationship allows the new medication to leverage a clinical heritage that includes more than 100,000 patient-years of real-world experience with its predecessor.^1,2

The pharmacological profile of milsaperidone is characterized by its rapid interconversion to iloperidone, resulting in dual active molecules that work in tandem. This mechanism involves the antagonism of dopamine D2, serotonin 5-HT2A, and alpha-1 adrenergic receptors. Research indicates that milsaperidone, formerly known as VHX-896, is the major active metabolite of iloperidone and is capable of crossing the blood-brain barrier.^1,2

Notably, milsaperidone exhibits a receptor binding profile where alpha-adrenergic binding exceeds its affinity for dopamine and serotonin receptors. This specific binding profile has prompted interest in investigating the drug’s potential efficacy in managing symptoms of hostility, agitation, and hyperarousal.^1,2

Clinical trials involving healthy volunteers and patients with schizophrenia or bipolar I disorder confirmed that the plasma concentration parameters for both drugs fall within the standard regulatory limits for bioequivalence. Beyond its current indications, milsaperidone is also being evaluated in an ongoing clinical study as a once daily adjunctive treatment for adults with treatment-resistant major depressive disorder (NCT06830044).²

The study for major depressive disorder is currently recruiting, and it will be used to determine the efficacy and safety of the medication compared with the placebo as an adjunctive therapy. Patients will be aged 18 years to 65 years and currently have an inadequate response to antidepressant therapy.³

Pharmacists should be aware of significant safety considerations and monitoring requirements associated with milsaperidone. The drug carries a boxed warning stating that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Therefore, milsaperidone is not approved for this patient population.¹

Clinical warnings also highlight the risk of QTc interval prolongation, which can lead to life-threatening arrhythmias such as torsade de pointes. To mitigate these risks, providers should avoid prescribing milsaperidone alongside other drugs known to prolong the QTc interval and should monitor serum potassium and magnesium levels in patients at risk for electrolyte disturbances.¹

Effective management of milsaperidone therapy also requires attention to metabolic changes and cardiovascular health. Common adverse reactions include tachycardia, dizziness, dry mouth, somnolence, and weight gain. Patients should be monitored for hyperglycemia, dyslipidemia, and orthostatic hypotension, the latter of which is most common during initial titration or dose increases.¹

Furthermore, the dosage must be adjusted for patients who are CYP2D6 poor metabolizers or those taking strong CYP2D6 or CYP3A4 inhibitors. Due to the potential for cognitive and motor impairment, patients should be advised to exercise caution when driving or operating machinery until they understand how the medication affects them.¹

Vanda Pharmaceuticals expects the medication to be commercially available in the third quarter of 2026.¹

READ MORE: Mental and Behavioral Health Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. Vanda Pharmaceuticals announces FDA approval of Bysanti (milsaperidone) for the treatment of bipolar I disorder and schizophrenia - a new chemical entity opening new horizons in psychiatric innovation. News release. Vanda Pharmaceuticals Inc. February 20, 2025. Accessed February 23, 2026. https://vandapharmaceuticalsinc.gcs-web.com/node/16771/pdf

2. Vanda Pharmaceuticals. Milsaperidone bioequivalence poster presented at ASCP 2025. Accessed February 23, 2026. https://www.vandapharma.com/pdfs/milsaperidone-BE-poster-ASCP-2025-v9-final-23may2025.pdf

3. Evaluation of efficacy and safety of milsaperidone as adjective therapy in patients with major depressive disorder. ClinicalTrials.gov identification: NCT06830044. Updated November 11, 2025. Accessed February 23, 2026. https://clinicaltrials.gov/study/NCT06830044